Gracell Biotechnologies Financials

GRCLDelisted Stock  USD 4.02  0.26  6.07%   
Based on the key indicators related to Gracell Biotechnologies' liquidity, profitability, solvency, and operating efficiency, Gracell Biotechnologies is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.
  
Understanding current and past Gracell Biotechnologies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Gracell Biotechnologies' financial statements are interrelated, with each one affecting the others. For example, an increase in Gracell Biotechnologies' assets may result in an increase in income on the income statement.

Gracell Biotechnologies Stock Summary

Gracell Biotechnologies competes with Monte Rosa, Design Therapeutics, Erasca, NextCure, and CytomX Therapeutics. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the Peoples Republic of China. The company was founded in 2017 and is headquartered in Suzhou, China. Gracell Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 348 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS38406L1035
Business AddressBuilding 12, Block
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.gracellbio.com
Phone86 512 6262 6701
CurrencyUSD - US Dollar

Gracell Biotechnologies Key Financial Ratios

Gracell Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Gracell Biotechnologies's current stock value. Our valuation model uses many indicators to compare Gracell Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gracell Biotechnologies competition to find correlations between indicators driving Gracell Biotechnologies's intrinsic value. More Info.
Gracell Biotechnologies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Gracell Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Gracell Biotechnologies Market Pulse

 Quote4.02
 Change(%)  6.07 
 Change0.26 
 Open4.28
 Low3.9
 High4.28
 Volume0
 ExchangeNASDAQ

Gracell Biotechnologies November 25, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Gracell Biotechnologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Gracell Biotechnologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Gracell Biotechnologies based on widely used predictive technical indicators. In general, we focus on analyzing Gracell Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Gracell Biotechnologies's daily price indicators and compare them against related drivers.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Consideration for investing in Gracell Stock

If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity